Mace Rothenberg - Articles and news items

Pfizer logo

Palbociclib receives FDA Breakthrough Therapy designation for potential treatment of patients with breast cancer

Industry news, News / 10 April 2013 / Pfizer

Palbociclib has received Breakthrough Therapy designation…

Pfizer logo

Pfizer’s Bosutinib receives positive opinion

Industry news, News / 18 January 2013 / Pfizer

“We are very pleased with this positive recommendation on bosutinib by the CHMP…”

Pfizer logo

U.S. Food and Drug Administration approves BOSULIF® (bosutinib)

Industry news, News / 4 September 2012 / Pfizer

“BOSULIF is the third new medicine to be approved by the FDA in just 13 months…”

Pfizer logo

Pfizer reports results from Phase 3 study of Torisel (temsirolimus)

Industry news, News / 10 August 2012 / Pfizer

Pfizer Inc. announced the Phase 3 INTORACT trial (B1771006) did not meet its primary endpoint…

Pfizer logo

Pfizer’s Crizotinib receives positive opinion for conditional marketing authorization from the CHMP

Industry news, News / 20 July 2012 / Pfizer

“The CHMP’s positive opinion brings us a step closer…”

Pfizer logo
Pfizer logo

Pfizer’s Axitinib receives positive opinion from the CHMP

Industry news, News / 25 May 2012 / Pfizer

The CHMP of the EMA has adopted a positive opinion regarding the marketing authorization of axitinib in the European Union (EU)…

Pfizer logo
Pfizer logo

Pfizer to present new data in advanced kidney, lung and Hhmatologic cancers

Industry news, News / 14 May 2012 / Pfizer

New data will be presented on targeted cancer treatments from the Pfizer Oncology portfolio across three key therapeutic categories…

Pfizer logo

U.S. Food and Drug Administration approves Pfizer’s INLYTA® (axitinib)

Industry news, News / 27 January 2012 / Pfizer

First treatment to demonstrate superior benefit in a Phase 3 study compared with another targeted agent in advanced RCC…

Pfizer logo

Pfizer to present clinical data from its hematology portfolio

Industry news, News / 7 November 2011 / Pfizer

Investigator research on several pfizer compounds to be presented…

Pfizer logo

Pfizer presents new Phase 3 data

Industry news, News / 18 May 2011 / Pfizer

Pfizer Inc. announced data from the pivotal Phase 3 AXIS 1032 trial. Patients with previously treated advanced RCC, axitinib extended progression-free survival…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...